Abstract
Purpose
This open-label study evaluated the effects of fentanyl buccal tablet (FBT) on functioning and mood in cancer patients with breakthrough cancer pain (BTcP).
Methods
Opioid-tolerant patients in seven European countries with up to four BTcP episodes/day received FBT doses (100–800 μg) identified during open-label titration to treat up to eight BTcP episodes during an open-label treatment period. In countries where FBT was not commercially available, patients could enter an open-label continuation phase. Functionality and satisfaction assessments included change from baseline to the end of the treatment period in the modified Brief Pain Inventory (BPI-7S) seven-item interference subscale, patient’s global assessment of satisfaction and ease of use, and Patient’s Global Impression of Change (PGIC). Safety was also assessed.
Results
Of 330 randomized patients, 218 completed the treatment period and 88 entered the continuation phase. Median background pain intensity was 4.0 (mild) throughout the study. After the treatment period, mean (SD) global modified BPI-7S score improved from 39.7 (15.9) at baseline to 31.6 (16.8) for a mean change of −8.6 (95 % confidence interval CI −10.5, −6.7; P < 0.0001), and 74.5 % of patients reported improvement in overall status (PGIC) compared with 25.5 % who reported no change or worsening (P < 0.001). Treatment-related adverse events (≥2 patients) during the continuation phase were application site erythema (6.9 %), application site swelling (4.6 %), and vertigo (4.6 %).
Conclusions
FBT may improve patient functioning, mood, and overall satisfaction in the management of BTcP. Long-term data did not indicate new safety concerns with FBT doses up to 800 μg.
Similar content being viewed by others
References
Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41:273–281
Portenoy RK, Payne D, Jacobsen P (1999) Breakthrough pain: characteristics and impact in patients with cancer pain. Pain 81:129–134
Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 1: prevalence and characteristics. J Opioid Manag 6:97–108
Zeppetella G, O'Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manag 20:87–92
Hwang SS, Chang VT, Kasimis B (2003) Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain 101:55–64
Caraceni A, Bertetto O, Labianca R et al (2012) Episodic (breakthrough) pain prevalence in a population of cancer pain patients. Comparison of clinical diagnoses with the QUDEI—Italian questionnaire for intense episodic pain. J Pain Symptom Manag 43:833–841
Davies AN, Dickman A, Reid C, Stevens AM, Zeppetella G (2009) The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. Eur J Pain 13:331–338
Mercadante S, Radbruch L, Caraceni A et al (2002) Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94:832–839
Portenoy RK, Bruns D, Shoemaker B, Shoemaker SA (2010) Breakthrough pain in community-dwelling patients with cancer pain and noncancer pain, part 2: impact on function, mood, and quality of life. J Opioid Manag 6:109–116
Caraceni A, Martini C, Zecca E et al (2004) Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med 18:177–183
FENTORA (2013) (fentanyl buccal tablet) [package insert]. Cephalon, Inc., Frazer
(2011) Effentora buccal tablets [package insert]. Maisons-Alfort, France: Cephalon Europe
Portenoy RK, Taylor D, Messina J, Tremmel L (2006) A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain 22:805–811
Slatkin NE, Xie F, Messina J, Segal TJ (2007) Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol 5:327–334
Weinstein SM, Messina J, Xie F (2009) Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: a long-term, open-label safety study. Cancer 115:2571–2579
Kleeberg UR, Davies A, Jarosz J et al (2014) Pan-European, open-label dose titration study of fentanyl buccal tablet in patients with breakthrough cancer pain. Eur J Pain. doi:10.1002/ejp.577
International Conference on Harmonisation Working Group ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use; June 10, 1996; Washington, DC. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6_R1/Step4/E6_R1__Guideline.pdf. Accessed March 1, 2011
Portenoy RK, Miransky J, Thaler HT et al (1992) Pain in ambulatory patients with lung or colon cancer. Prevalence, characteristics, and effect. Cancer 70:1616–1624
Taylor DR, Webster LR, Chun SY et al (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal fentanyl citrate (OTFC, ACTIQ). Pain Med 8:281–288
Farrar JT, Young JP Jr, LaMoreaux L, Werth JL, Poole RM (2001) Clinical importance of changes in chronic pain intensity measured on an 11-point numerical pain rating scale. Pain 94:149–158
Webster LR, Messina J, Xie F, Nalamachu S (2011) Effect of fentanyl buccal tablet on pain-related anxiety: a 4-week open-label study among opioid-tolerant patients with chronic and breakthrough pain. J Opioid Manag 7:297–308
Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J (2011) Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain. Curr Med Res Opin 27:519–530
Uberall MA, Muller-Schwefe GH (2011) Sublingual fentanyl orally disintegrating tablet in daily practice: efficacy, safety and tolerability in patients with breakthrough cancer pain. Curr Med Res Opin 27:1385–1394
Davies A, Sitte T, Elsner F et al (2011) Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain. J Pain Symptom Manag 41:358–366
Mercadante S, Radbruch L, Davies A et al (2009) A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin 25:2805–2815
Acknowledgments
This study was sponsored by Cephalon, Inc. (Frazer, PA), now a wholly owned subsidiary of Teva Pharmaceuticals Industries Ltd. Writing support was provided by Bina J. Patel, PharmD, of Peloton Advantage, LLC, funded by Teva Pharmaceuticals. The authors wish to thank Ronghua Yang, PhD, of Teva Pharmaceuticals for assistance with the statistical analysis and acknowledge the 135 investigators for their contributions to the study.
Conflict of interest
The authors have full control of all primary data and allow the journal to review these data if requested. A. Davies has received honoraria from Cephalon and Teva Pharmaceuticals for speaking at symposia and attending advisory boards, as well as unrestricted funding to support research. H. G. Kress has received honoraria as a speaker and consultant from Cephalon/Teva Pharmaceuticals. At the time of this study, H. Schneid was an employee of Cephalon, Inc. (Maisons-Alfort, France), now a wholly owned subsidiary of Teva Pharmaceuticals (Petah Tikva, Israel).
Author information
Authors and Affiliations
Corresponding author
Additional information
This study was previously presented at (1) The 15th World Congress of Pain Clinicians (WSPC); June 27-30, 2012; Granada, Spain; (2) The International Association for the Study of Pain’s (IASP) 14th World Congress on Pain; August 27-31, 2012; Milan, Italy; and (3) The European Society for Medical Oncology (ESMO) 2012 Congress; September 28-October 2, 2012; Vienna, Austria.
Rights and permissions
About this article
Cite this article
Davies, A., Kleeberg, U.R., Jarosz, J. et al. Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. Support Care Cancer 23, 2135–2143 (2015). https://doi.org/10.1007/s00520-014-2590-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00520-014-2590-8